Huang Lei, Weil Max Harry, Sun Shijie, Tang Wanchun, Fang Xiangshao
The Institute of Critical Care Medicine, Palm Springs, CA, USA.
J Cardiovasc Pharmacol Ther. 2005 Jun;10(2):113-20. doi: 10.1177/107424840501000205.
Earlier studies have implicated the adverse effects of beta- and alpha(1)-adrenergic receptors during cardiopulmonary resuscitation (CPR). Because carvedilol is both a nonselective beta- and alpha1-selective adrenergic receptor-blocking agent, we hypothesized that pretreatment with carvedilol would convert the actions of epinephrine to that of a selective alpha2-agonist.
Ventricular fibrillation (VF) was induced in Sprague-Dawley rats weighing approximately 500 g. Animals were randomized to 4 groups of 5 animals each: (1) placebo pretreatment and epinephrine treatment, (2) carvedilol pretreatment and placebo treatment, (3) carvedilol pretreatment and epinephrine treatment, and (4) placebo pretreatment and placebo treatment. Carvedilol (50 microg/kg) was injected as a bolus into the right atrium 15 minutes before VF was induced. VF was untreated for 8 minutes, after which CPR (chest compression and mechanical ventilation) was begun. Epinephrine (30 microg/kg) was injected into the right atrium 2 minutes after the start of CPR. Electrical defibrillation was attempted after 14 minutes of VF.
All but 2 animals were successfully resuscitated. Approximately equivalent increases in coronary perfusion pressure from 23 +/- 1 mm Hg to 30 +/- 3 mm Hg were observed after the injection of epinephrine independently of carvedilol pretreatment. Carvedilol pretreatment followed by epinephrine treatment reduced early postresuscitation ventricular ectopy (116 +/- 147 vs 834 +/- 380, P < .01) and minimized increases in arterial blood lactate at 5 minutes after resuscitation (10.9 +/- 2.1 mmol/L vs 17.4 +/- 3.5 mmol/L, P < .01). The postresuscitation cardiac index measured 4 hours later was increased (307 +/- 43 mL x min(-1) x kg(-1) vs 210 +/- 6 mL x min(-1) x kg(-1), P < .05). Left ventricular diastolic pressures were decreased (6 +/- 1 vs 14 +/- 1 mm Hg, P < .05). Animals pretreated with carvedilol survived longer (71 +/- 1 vs 45 +/- 22 hours, P < .05) and with less postresuscitation neurologic deficit.
After beta- and alpha1-adrenergic blockade with carvedilol before inducing cardiac arrest, epinephrine administered during CPR yielded better postresuscitation myocardial and neurologic functions and significantly increased postresuscitation survival.
早期研究表明,β-肾上腺素能受体和α1-肾上腺素能受体在心肺复苏(CPR)过程中具有不良影响。由于卡维地洛是一种非选择性β-肾上腺素能受体阻滞剂和α1-选择性肾上腺素能受体阻滞剂,我们推测,卡维地洛预处理可将肾上腺素的作用转变为选择性α2-激动剂的作用。
在体重约500 g的Sprague-Dawley大鼠中诱导室颤(VF)。将动物随机分为4组,每组5只:(1)安慰剂预处理加肾上腺素治疗;(2)卡维地洛预处理加安慰剂治疗;(3)卡维地洛预处理加肾上腺素治疗;(4)安慰剂预处理加安慰剂治疗。在诱导VF前15分钟,将卡维地洛(50μg/kg)作为推注剂注入右心房。VF持续8分钟不予处理,之后开始进行CPR(胸外按压和机械通气)。在CPR开始2分钟后,将肾上腺素(30μg/kg)注入右心房。VF持续14分钟后尝试进行电除颤。
除2只动物外,其余均成功复苏。注射肾上腺素后,无论是否进行卡维地洛预处理,冠状动脉灌注压均有近似的升高,从23±1 mmHg升至30±3 mmHg。卡维地洛预处理后再给予肾上腺素治疗,可减少复苏后早期的室性异位搏动(116±147次 vs 834±380次,P<.01),并使复苏后5分钟时动脉血乳酸水平的升高最小化(10.9±2.1 mmol/L vs 17.4±3.5 mmol/L,P<.01)。复苏4小时后测量的复苏后心脏指数升高(307±43 mL·min-1·kg-1 vs 210±6 mL·min-1·kg-1,P<.05)。左心室舒张压降低(6±1 mmHg vs 14±1 mmHg,P<.05)。经卡维地洛预处理的动物存活时间更长(71±1小时 vs 45±22小时,P<.05),且复苏后神经功能缺损较少。
在诱导心脏骤停前用卡维地洛进行β-和α1-肾上腺素能受体阻滞,CPR期间给予肾上腺素可使复苏后心肌和神经功能更好,并显著提高复苏后的生存率。